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Background: The prediction of pathological outcomes prior to surgery remains a challenging problem for the
appropriate surgical indication of prostate cancer. This study was performed to identify preoperative values
predictive of pathological and oncological outcomes based on standardized extended prostate biopsies with core
histological results diagrammed/mapped in patients receiving radical prostatectomy for prostate cancer clinically
diagnosed as localized or locally advanced disease.
Methods: In 124 patients with clinically localized or locally advanced prostate cancer (cT1c–cT3a) without prior
treatment, pathological outcomes on the surgical specimen including seminal vesicle involvement (SVI), positive surgical
margin (PSM), and perineural invasion (PNI) were studied in comparison with clinical parameters based on the results of
14-core prostate biopsies comprising sextant, laterally-directed sextant, and bilateral transition zone (TZ) sampling.
Results: Concerning the association of pathological outcomes with oncological outcomes, patients with PSM and PNI on
surgical specimens had poorer biochemical-progression-free survival than those without PSM (logrank p=0.002) and PNI
(p= 0.003); it was also poorer concerning SVI, although the difference was not significant (p= 0.120). Concerning the
impact of clinical parameters on these pathological outcomes, positive TZ and multiple positive biopsy cores in the
prostatic middle were independent values predictive of SVI with multivariate analyses (p= 0.020 and p=0.025,
respectively); both positive TZ and multiple positive prostatic middle biopsies were associated with larger tumor volume
(p< 0.001 in both). The percentage of positive biopsy cores (%positive cores) and biopsy Gleason score were
independent values predictive of PSM (p=0.001) and PNI (p= 0.001), respectively. Multiple positive cores in the prostatic
base were associated with proximal/bladder-side PSM (p< 0.001), and also linked to poorer biochemical-progression-free
survival (p= 0.004). Clinical T stage had no association with these pathological outcomes.
Conclusions: %positive cores and Gleason score in extended biopsies were independent values predictive of PSM and
PNI in prostate cancer clinically diagnosed as localized or locally advanced disease, respectively, which were associated
with poorer oncological outcomes. When diagramming biopsy-core results, extended biopsy may provide additional
information for predicting oncological and pathological outcomes including SVI in patients clinically diagnosed as having
localized or locally advanced disease.
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Age at diagnosis, mean (range) 63.8 (40 – 73)
PSA levels at diagnosis (ng/ml) No. of patients
< 4.0 13 (10.5%)
4.0 – 10.0 75 (60.5%)
10.1 – 20.0 29 (23.4%)
20.1 – 50.0 6 (4.8%)
50.1 or higher 1 (0.8%)
Gleason score at biopsy No. of patients
6 48 (38.7%)
3 + 4 20 (16.1%)
4 + 3 20 (16.1%)
8 or higher 36 (29.0%)
PSA, prostate-specific antigen.Background
Since the advent of the preoperative staging table/nomo-
gram, the clinical staging of localized or locally advanced
prostate cancer has been revolutionized both for radical
surgery and radiotherapy [1-3]. These predictive scales are
used for the calculation of possible oncological outcomes
or probability of extraprostatic extension in the pathological
stage, for example, seminal vesicle involvement (SVI), by
combining clinical parameters/variables such as serum
variable prostate-specific antigen levels, digital rectal exam-
ination findings, Gleason score at prostate biopsy, and per-
centage of positive biopsy cores (%positive cores) [1-3].
Although extraprostatic disease does not necessarily indi-
cate incurable disease, SVI has been associated with poor
oncological outcomes [3-6]. However, advances in the
aforementioned staging modalities have led to the low
prevalence of SVI in pathological outcomes, and it has been
reported that the recent low prevalence of SVI makes the
validation of prognostic models difficult [7]. On the other
hand, positive surgical margin (PSM) and perineural inva-
sion (PNI) have also been suggested to have a prognostic
value [6,8], but clinical parameters predictive of PSM re-
main controversial and studies on PNI are limited. The pre-
diction of these pathological outcomes prior to surgery is
significant in clinical practice, but there has been no study
examining which clinical parameters reflect each of SVI,
PSM, and PNI; such analyses may confirm the feasibility of
staging nomograms also based on pathological approaches.
Several previous studies assessed pathological outcomes
such as SVI in comparison with observations using conven-
tional sextant to octant biopsies [9,10], but there has been
no study examining predictive values for the mentioned
pathological outcomes based on extended/extensive pros-
tate biopsies that may potentially provide more accurate in-
formation concerning the disease condition and extension
[11]. The aim of the present study was to identify preopera-
tive clinicopathological factors associated with SVI, PSM,
and PNI, based on standardized extended prostate biopsies
with core histological results precisely diagrammed in men
who underwent radical prostatectomy for prostate cancer
clinically diagnosed as localized or locally advanced disease.
In addition, oncological outcomes were assessed to clarify
whether such factors identified based on extended biopsy
results also have a prognostic value in them.
Methods
Patients
We reviewed 144 consecutive patients, who were diag-
nosed with prostate cancer based on standardized 14-
core prostate biopsy described elsewhere and treated
with standardized radical prostatectomy with standardor modified pelvic lymphadenectomy for localized or lo-
cally advanced prostate cancer (cT1c–3a N0 M0) at our
institution between June 2003 and March 2010. Twenty
patients who received prior therapy such as androgen
deprivation or radiotherapy were excluded. The final
study group comprised 124 patients. All surgical proce-
dures were performed by an experienced urologist (HK)
with assistance by experienced urologists (NH and AT).
The procedure for this research project was approved by
the Ethics Committee of our institution. Informed con-
sent was obtained from all patients.
Clinical stages were determined according to the Inter-
national Union Against Cancer (UICC) classification of
2009. Clinical staging routinely included abdominal and
pelvic computerized tomography (CT), chest radiograph
or thoracic CT, isotope bone scanning, and extended/ex-
tensive prostate biopsy, as described elsewhere. Patients’
demographics are shown in Table 1. PSA levels at diagno-
sis ranged between 2.6 and 63.7 (mean: 9.0 ng/ml), and
Gleason score at biopsy ranged between 6 and 10. Bio-
chemical progression/PSA failure after surgery was defined
as 2 consecutive PSA values of 0.2 ng/ml or greater at any
time postoperatively, or any additional treatment more
than 6 months after radical prostatectomy [12]. Five
patients receiving adjuvant androgen deprivation therapy
immediately after surgery were excluded from survival
analyses. The mean and median observation periods were
31.0 and 24.0 months, respectively.
Prostate biopsy
Transrectal 14-core systemic prostate biopsies were car-
ried out using transrectal ultrasound Aloka SSD 3300
CV (Aloka, Tokyo, Japan) following the method of
standard sextant biopsy, in addition to those for sextant
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tion zone biopsy, as described previously [13]; 14 cores
thus comprised 4 cores for each of the prostatic base,
middle, and apex, and 2 cores for the transition zone.
We separated the patients to subgroups based on those
with a single positive core or multiple positive cores in
each of the prostatic apex, middle, and base; this dichoto-
mization was determined based on previous studies
reporting that a single positive core in sextant or less biop-
sies is a requirement for categorizing to low-risk disease
[14]. The maximal core length obtained by needle biopsy
was 22 mm; the mean measured core length was
15.9± 3.2 mm. Each core was tagged and mapped to pro-
duce histological localization diagrams (Figure 1).
Histopathological diagnosis
An independent pathologist (MK) made all histopatho-
logical diagnoses, and standardized grading was carried
out according to the contemporary Gleason classifica-
tion system [15]. All pathological examinations were
performed using the whole-mount step-section tech-
nique. The prostate was weighed, measured, and inked,
and was subsequently fixed in buffered formalin for at
least 24 hours before sectioning. Following fixation, the
specimen was step-sectioned, and was submitted in en-
tire cross-sections from the apex to base at 3 – 5-mm
intervals; the mean number of sections was 27.1 ± 6.6.
The apex and bladder neck were coned and serially sec-
tioned. Cancer foci were also diagrammed in photo-
graphs of the sectioned specimen. SVI was defined
following the criteria of Epstein et al., as the invasion to
the muscular wall of the seminal vesicle [16]. PNI in the
radical prostatectomy specimens was assessed following
the method reported previously [17-19]. Surgical mar-
gins were assessed adopting an approach similar to that
in the recent consensus criteria [20].
Statistical analysis
In addition to the chi-square and Fisher's exact tests, the
Mann–Whitney U test was used to compare unpaired para-







Figure 1 Histological localization diagram in a 67 year-old man with
segments in cores as bars painted in black (TZ, transition zone; PZ, p
core segments.values were identified with multivariate analysis using a lo-
gistic regression model; variables having p-value of p< 0.1
in univariate analyses were tested with multivariate analysis.
Statistical analysis of Gleason score was performed with a
stepwise model. Survival curves were generated using the
method of Kaplan and Meier, and differences between
curves were evaluated employing the log-rank test. Uni-
and multivariate analyses for survival-associated parameters
were performed using Cox proportional hazard models.
Correlations between parameters were analyzed using
Spearman’s rank correlation coefficient (rs) analysis. The
test was two-sided except for the Fisher's exact test, and p
< 0.05 was considered significant. All analyses were per-
formed using SPSS version 15.0 J (SPSS Inc., Chicago, IL,
USA) on a Windows-based computer.
Results
Pathological stage and Gleason score in radical
prostatectomy specimens
There were 81 (65.3%) with pT2 and 42 (33.9%) patients
with pT3 disease. Thirty-six (29.3%) and 4 (3.2%) of the
patients experienced pathological upstaging from and
downstaging, respectively. One patient had pT0 disease.
Also, there were 48 (38.7%) with pathological Gleason
score of 6, 40 (32.3%) with pathological Gleason score of
7, and 36 (29.0%) patients with pathological Gleason
score of 8 or higher. Forty-eight (39.0%) and 27 (22.0%)
of the patients experienced upgrade and downgrade of
Gleason score, respectively.
Relationship between SVI and clinical parameters or
biopsy findings
Table 2 shows the relationships between the presence/
absence of SVI and clinical parameters or tumor locali-
zations based on prostate biopsies. PSA levels, %positive
cores, and the cT stage were not different between those
with and without SVI. Patients with SVI showed a higher
Gleason score at biopsy, higher rate of multiple (2 or
more) positive cores in the prostatic middle, and a
higher transition zone-positive rate, compared with







6 positive cores in 14-core prostate biopsy, showing positive
eripheral zone); each core was histologically assessed in 3 divided









P value P value Adjusted odds ratio (95% CI)
Mean age [years] 63.6 ± 3.9 63.9 ± 5.1 0.725
PSA [ng/ml] 13.0 ± 8.1 8.7 ± 7.2 0.105
Gleason score at biopsy 8.1 ± 1.1 7.0 ± 1.0 0.005
cT stage (n) 0.153
T1c 5 (62.5%) 94 (81.0%)
T2 3 (37.5%) 15 (12.9%)
T3a 0 (0%) 7 (6.0%)
%positive cores 31.0 ± 21.3 21.3 ±16.4 0.242
TZ biopsy positive (n) 7 (87.5%) 35 (30.2%) 0.002 0.023 12.99 (1.490-111.1)
Number of apex-positive (2–4/0–1) (n) 3/5 26/90 0.278
Number of middle-positive (2–4/0–1) (n) 6/2 28/88 0.005 0.025 7.299 (1.312-40.00)
Number of base-positive (2–4/0–1) (n) 4/4 23/93 0.067
PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middle, prostatic middle biopsy; base, prostatic base biopsy.
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regression model, positive transition zone (adjusted odds
ratio: 12.99 [95%CI: 1.490–111.1], p = 0.023) and mul-
tiple positive biopsies in the prostatic middle (adjusted
odds ratio: 7.299 [95%CI: 1.312–40.00], p = 0.025) were
independent values predictive of seminal vesicle
involvement.
Results when analyzing data on each of the standard
sextant sites or laterally-directed sextant cores had no as-
sociation with pathological outcomes (data not shown).
When assessed with tumor localization in radical pros-
tatectomy specimens, the positive-predictive value of
TZ biopsy was 0.86; 86% of the patients with positive
TZ biopsy also had TZ cancer or cancer invading to TZ
in surgical specimens. All of the patients with positive
prostatic middle biopsy also had cancer foci in the pros-
tatic middle in surgical specimens. The largest tumor size
ranged between 2 – 45 (mean: 16.8 ± 9.4) mm (pT0 in one
patient) in prostatectomy specimens; patients with a
positive TZ biopsy had a larger tumor size than those with
a negative TZ biopsy (mean 21.5± 10.2 mm vs.
14.2± 7.8 mm, respectively, P< 0.001). Also, patients with
multiple positive cores in prostatic middle biopsy had a
larger tumor size than those with no or a single positive
core in prostatic middle biopsy (mean: 22.0± 11.3 mm vs.
14.9± 7.7 mm, respectively, P< 0.001).
Relationship between PSM and clinical parameters or
biopsy findings
Table 3 shows the relationships between the presence/
absence of PSM and clinical parameters or tumor locali-
zations based on prostate biopsies. Data on the surgical
margin were not available in 4 patients. PSA levels,biopsy Gleason score, and cT stage were not different
between those with and without PSM. Patients with
PSM showed higher %positive cores and a higher rate of
multiple positive cores in the prostatic base, middle, and
apex, compared with those without PSM (p = 0.001,
0.049, 0.004, and 0.037, respectively); with multivariate
analyses using the logistic regression model, %positive
cores was an independent value predictive of PSM
(adjusted odds ratio: 1.044 [95%CI: 1.019-1.070],
p = 0.001, Table 4). %positive cores was also correlated
with the largest tumor size in prostatectomy specimens
(rs = 0.354, p< 0.001).
Relationship between PNI and clinical parameters or
biopsy findings
Table 4 shows the relationships between the presence/
absence of PNI and clinical parameters or tumor locali-
zations based on prostate biopsies. Gleason score on
biopsy alone was higher in patients with than in those
without PNI (univariate p< 0.001, multivariate p = 0.001,
adjusted odds ratio: 1.983 [95%CI: 1.342-2.929]).
Oncological outcomes
Five men receiving immediate adjuvant androgen
deprivation therapy and those with missing data were
excluded from survival analyses to assess appropriate
biochemical progression. Regarding pathological out-
comes, patients with PSM had poorer biochemical-
progression-free survival than those without PSM
(logrank p = 0.002), and this was also the case for PNI
(p=0.003) (Figure 2). Although patients with SVI
seemingly showed a lower biochemical-progression-free
survival rate than those without SVI, the difference









p-value P value Adjusted odds ratio (95% CI)
Mean age [years] 63.5 ± 36.0 64.0 ± 4.6 0.993
PSA [ng/ml] 9.8 ± 6.3 8.7 ± 7.8 0.247
Gleason score at biopsy 7.2 ± 1.2 7.0 ± 1.0 0.209
cT stage (n) 0.347
T1c 30 (76.9%) 65 (80.2%)
T2 5 (12.8%) 13 (16.0%)
T3a 4 (10.3%) 3 (3.7%)
%positive cores 31.0 ± 21.3 21.3 ±16.4 0.001 0.001 1.044 (1.019-1.070)
TZ biopsy positive (n) 17 (43.6%) 24 (29.6%) 0.131
Number of apex-positive (2–4/0–1) (n) 14/25 15/66 0.037
Number of middle-positive (2–4/0–1) (n) 17/22 15/66 0.004
Number of base-positive (2–4/0–1) (n) 13/26 14/67 0.049
PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middle, prostatic middle biopsy; base, prostatic base biopsy. Data not available in 4
patients.
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p=0.120) (Figure 2). Among preoperative clinical para-
meters, patients with PSA levels of 10 ng/ml or higher had
poorer biochemical-progression-free survival than those
with PSA levels less than 10 ng/ml (p= 0.033).
Biochemical-progression-free survival was lower in
patients with biopsy Gleason score of 8 or higher than in
those with Gleason score of<=7 (p= 0.027). Patients with
%positive cores of>= 35.7% (number of positive cores of
5 or more) showed poorer biochemical-progression-free
survival than those with %positive cores of< 35.7%
(p=0.023). Patients with multiple positive cores in the








Mean age [years] 63.7 ± 5.0 64.0 ± 5.0
PSA [ng/ml] 9.5 ± 5.9 8.5 ± 8.5
Gleason score at biopsy 7.4 ± 1.1 6.7 ± 0.9
cT stage (n)
T1c 49 (77.8%) 50 (82.0%)
T2 9 (14.3%) 9 (14.8%)
T3a 5 (7.9%) 2 (3.3%)
%positive cores 23.5 ± 18.7 19.8 ±14.8
TZ biopsy positive (n) 24 (38.1%) 18 (29.5%)
Number of apex-positive (2–4/0–1) (n) 14/49 15/46
Number of middle-positive (2–4/0–1) (n) 21/42 13/48
Number of base-positive (2–4/0–1) (n) 17/46 10/51
PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middsurvival (p= 0.004); patients with multiple positive cores in
the prostatic base more frequently had proximal/bladder-
side PSM than those with a single or no positive core in
the prostatic base (48.1 vs. 6.5%, respectively, p< 0.001).
We additionally showed biochemical-progression-free
survivals according to pT stage (Figure 3).
Discussion
In the present study, PSM was a significant pathological
factor associated with poorer oncological outcomes, and
%positive cores was an independent value predictive of
PSM (multivariate p = 0.001) showing a prognostic sig-
nificance (p = 0.023) in patients with prostate cancerers between patients with and without peruneural
Univariate Multivariate
P value P value Adjusted odds ratio (95% CI)
0.894
0.104


























































Figure 2 Biochemical-progression-free survival in patients with or without seminal vesicle involvement (SVI, A), a positive surgical
























Figure 3 Biochemical-progression-free survivals categorized
according to pathological T (pT) stage.
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disease. These results suggest that %positive cores based
on extended biopsies may be useful for predicting onco-
logical outcomes. %positive cores theoretically reflects
the tumor volume [21], and thus is a feasible index for
predicting PSM. In addition, patients with multiple posi-
tive cores in the prostatic base had poorer oncological
outcomes, and they more frequently had proximal/blad-
der-side PSM than those with a single or no positive core
in the prostatic base (48.1 vs. 6.5%, respectively, p
< 0.001). Several previous studies have reported that
proximal-side PSM is an adverse prognostic factor [22],
and it has also been shown that positive cores in the
prostatic base are associated with a higher rate of prox-
imal PSM [23], but the relevant previous studies did not
perform survival analyses. The present study additionally
suggested that multiple positive cores in the prostatic
base with extended biopsy protocol possibly have a prog-
nostic significance, although further studies are required
to draw a conclusion.
Previous studies have reported the frequency of PNI in
radical prostatectomy specimens to be between 32 and
79%. [19-21], and it was about 50% in the present study
(Table 3). A few studies reported that the presence ofPNI is associated with poor oncological outcomes [8],
and our study also supported the prognostic value of
PNI. The current study also suggested that biopsy Glea-
son score was an independent value predictive of PNI. It
has been shown that PNI of prostate cancer is relevant
to a tumor’s invasive capacity [24], while Gleason score
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lation to the expression of matrix metalloproteinases
[25,26]. A study regarding the diagnostic value of PNI in
extended biopsy cores is currently underway.
Recent advances in staging modalities and surgical indi-
cations have been associated with the low prevalence of
SVI in surgical outcomes, and it has been reported that
the recent low prevalence of SVI makes the validation of
prognostic models/nomogram difficult [7]. SVI did not
have a prognostic significance in the present study most
probably due to the small number of those with SVI; the
survival curves categorized with and without SVI
seemingly separated (Figure 2). Additionally, the 5 patients
excluded from survival analyses because of immediate in-
ception of adjuvant androgen deprivation therapy showed
SVI, and their exclusion probably contributed to the ab-
sence of statistical significance for SVI. There has been no
study examining associations between these pathological
conditions and the results of precisely profiled extended
biopsy. When mapping/diagramming positive cores,
extended biopsy may be of value to predict SVI in patients
with prostate cancer clinically diagnosed as localized
disease. Interestingly, the number/percentage of positive
cores calculated for the standard sextant sites or laterally-
directed sextant cores did not reflect SVI, whereas positive
TZ and multiple positive cores in the prostatic middle
were independently associated with SVI. However,
positive-predictive value of TZ biopsy assessed with tumor
localization in the prostatectomy specimen was 0.86, sug-
gesting contaminations of cancer arising from the
peripheral zone. Patients with a positive TZ biopsy or
multiple positive cores in prostatic middle biopsy had a
larger tumor size in prostatectomy specimens. With the
current 14-core biopsy protocol, parameters such as posi-
tive TZ and multiple positive cores in the prostatic middle
possibly reflect the tumor size, and thus are associated
with SVI. To validate the significance of these observa-
tions, studies comparing various biopsy protocols are
needed.
In the present study with the mentioned extended
biopsy protocol, positive TZ and multiple positive cores
in the prostatic middle were independently correlated
with SVI (p = 0.020 and p = 0.023, respectively). Also, %
positive cores was an independent factor predictive of
PSM (p= 0.001), and biopsy Gleason score was inde-
pendently correlated with PNI (p = 0.001). Thus, clinical
factors predictive of pathological outcomes varied among
SVI, PSM, and PNI; these results suggest that prevailing sta-
ging nomograms or risk-assessment scoring systems com-
bining multiple values such as Gleason score and %positive
cores are practically possible based on the pathological ap-
proach employing extended biopsy protocols [1-3].
Additionally, artificial intelligence techniques such as artifi-
cial neural networks incorporating mentioned informationsobtained from extended biopsies potentially support
decision-making in prostate cancer treatment [27].
In this study, one patient (0.8%) had pT0 disease, and
the frequency was similar to those in previous reports [28].
The present study had several limitations. The study was
retrospectively designed, and the relatively small number
of patients may have led to a limited statistical power. Also,
the small number of locally advanced disease cases is a
limitation of this type of study; surgical indication probably
affected the background of the study group, as discussed
elsewhere. Further follow-up studies are warranted to con-
firm the significance of the observations on oncological
outcomes in men with localized prostate cancer.
Conclusions
PSM and PNI were significant pathological factors asso-
ciated with poorer oncological outcomes, and %positive
cores and Gleason score in extended biopsies were inde-
pendent values predictive of PSM and PNI in patients with
prostate cancer clinically diagnosed as localized disease,
respectively. When mapping/diagramming positive cores,
extended prostate biopsies may provide additional value in
the prediction of oncological and pathological outcomes
such as SVI; multiple positive cores in the prostatic base
possibly lead to poorer oncological outcomes.
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